Kurzfassung

NETU-08-03 A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group,Prospective Study to Assess the Efficacy, Safety and Tolerability of Three Oral Doses of Netupitant Given Once a Day (50, 100 and 200 mg) vs Placebo in Patients with Overactive Bladder.